PT Diastika Biotekindo Tbk (CHEK) Fair Value & Analysis
Healthcare · ID · Market cap 551B IDR
Fair value as of: Jul 19, 2026
From 15 valuation models · updated 23 days ago
Share price +8.1% over the past month.
Below-average quality, and screening another 49% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (85.23 IDR). The favourable scenario is already priced in.
- Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (13 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 19, 2026.
How to read this chart
13‑month range 111.00 IDR – 210.00 IDR · fair‑value band 51.14 IDR – 85.23 IDR · the 134.00 IDR price screens above the 68.18 IDR fair value. As of Jul 19, 2026.
Analysis
PT Diastika Biotekindo Tbk (CHEK) currently trades at 134.00 IDR, while our model-based Fair Value estimate is 68.18 IDR, implying the stock looks roughly 49.1% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, PT Diastika Biotekindo Tbk generated revenue of 203B IDR at a net margin of 6.2%. Revenue grew 4.9% year over year. It earns a return on equity of 8.3%. Fundamentals as of Jul 19, 2026
Our scenario range runs from 51.14 IDR (bear case) to 85.23 IDR (bull case); at 134.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 44% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -49%, CHEK screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Growth Earnings (116.23 IDR) versus Dividend Discount (13.79 IDR). Highest evidence: Residual Income (76).
Notify me when CHEK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease.
Full company description
PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease. It also provides life science products that are processed from biological products. In addition, the company engages in general trading, laboratory equipment, research, medicine, export and import, pharmaceutical chemicals, services, electronics, and industrial activities. PT Diastika Biotekindo was founded in 1989 and is headquartered in Jakarta Timur, Indonesia. PT Diastika Biotekindo Tbk is a subsidiary of PT Optel Investama Mulia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
PT Diastika Biotekindo Tbk reported revenue of 201B IDR in FY2025 versus 129B IDR in FY2023, a compound +24.9%/yr. Reported net income was 14.0B IDR in FY2025, compounding +1.6%/yr from FY2023.
CHEK screens 49% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare PT Diastika Biotekindo Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Diastika Biotekindo Tbk (CHEK) overvalued or undervalued?
What is the fair value of CHEK?
What is the quality score of CHEK?
What is the revenue of PT Diastika Biotekindo Tbk (CHEK)?
What is the net profit margin of CHEK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Diastika Biotekindo Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.